Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective.
Drug Resist Updat
; 13(1-2): 29-43, 2010.
Article
em En
| MEDLINE
| ID: mdl-20167530
ABSTRACT
Our increased understanding of the molecular processes underlying cellular sensitivity to ionizing radiation has led to the identification of novel targets for intervention. New agents have become available for combined use to overcome radioresistance and enhance the clinical efficacy of radiotherapy. This rational selection of potential radiosensitizers contrasts with the empirical approach that has dominated the field of chemo-radiotherapy over the last decades. It allows the identification of those patients who will benefit most from a specific combination by exploiting new predictive biomarkers of response. In this review we present several approaches of targeted radiosensitization and discuss the available in vitro and in vivo results that support their translation into clinical trials. We focus on EGFR-inhibiting, anti-angiogenic, apoptosis-modulating and PARP-interfering strategies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Radioterapia
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Drogas em Investigação
/
Sistemas de Liberação de Medicamentos
/
Terapia Combinada
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Drug Resist Updat
Assunto da revista:
ANTINEOPLASICOS
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Holanda